News: 2021

ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

March 03, 2021
ISA106's promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-1...
Read more
ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

February 16, 2021
-- Phase 1 study to investigate safety and preliminary efficacy of lead candidate, INT-1B3 --
Read more
InteRNA Technologies Announces Dosing of First Patient in  First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

February 12, 2021
Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

February 09, 2021
-- Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic --
Read more
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®

January 26, 2021
Combination aimed at priming and driving durable patient immune responses to cancer
Read more
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®

Sapreme Appoints Henrik Luessen as Chief Business Officer

January 21, 2021
Appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer at Sapreme
Read more
Sapreme Appoints Henrik Luessen as Chief Business Officer

Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a...
Read more
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

January 12, 2021
Merus N.V. today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness...
Read more
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

ISA106 - SLP therapeutic for COVID-19

January 11, 2021
Interview with ISA Pharmaceuticals' CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cel...
Read more
ISA106 - SLP therapeutic for COVID-19

Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

January 11, 2021
Clinical data from Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of C...
Read more
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

Macrophage Pharma expands Executive team with CSO and CTO

January 09, 2021
Key hires enhance management for next development phase
Read more
Macrophage Pharma expands Executive team with CSO and CTO

Klinische Fase 1a studie met lead compound INT-1B3

January 07, 2021
December 2020: Net voor Kerst in de bijlage van Het Algemeen Dagblad - InteRNA heeft klinische Fase 1a studie met lead compound...
Read more
Klinische Fase 1a studie met lead compound INT-1B3

Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

January 07, 2021
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
Read more
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

January 06, 2021
• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 • Evaluation of Cristal's CliCr® and I...
Read more
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms

Home > News > Archive

© 2021 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds